The results of the analysis from a phase 3 randomised controlled trial, published in The Lancet journal, suggest that the interval between doses can be safely extended to three months given the protection a single dose offers.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.